Clinical Use of GnRH Agonists in Canine and Feline Species

Reproduction in Domestic Animals

Volumn 46, Issue 2, 2011, Pages 344-353

  Fontaine, E ^a   Fontbonne, A ^a  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN;

ANIMAL; ANIMAL DISEASE; CAT; CONTRACEPTION; DOG; DRUG EFFECT; DRUG POTENTIATION; ESTRUS; FEMALE; MALE; METHODOLOGY; OVULATION; REVIEW;

ANIMALS; CATS; DOGS; ESTRUS; FEMALE; GONADOTROPIN-RELEASING HORMONE; MALE; OVULATION; STERILIZATION, REPRODUCTIVE;

ANIMALIA; FELIDAE; MAMMALIA;

EID: 79952582255     PISSN: 09366768     EISSN: 14390531     Source Type: Journal    
DOI: 10.1111/j.1439-0531.2010.01705.x     Document Type: Review

References (79)

1. Anderson A, Simpson M, 1973: The ovary and reproductive cycle of the dog (Beagle). Geron-X Inc., Los Atos, CA.
2. Atltintas D, Kokcu A, Tosun M, Cetinkaya M, Kandemir B, 2008: Comparison of the effect of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis. J Obstet Gynaecol Res, 34, 1014-1019.
3. Bahk J, Kim M, Park M, Lee H, Lee J, Chung B, Min S, 2008: Gonadotrophin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int, 80, 431-438.
4. Basaria S, Lieb JN, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs A, 2002: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56, 779-786.
5. Blumenfeld Z, 2007: How to preserve fertility in young women exposed to chemotherapy? The role of GnRh agonist cotreatment in addition to cryopreservation of embrya, oocytes or ovaries Oncologist, 12, 1044-1054.
6. Brufsky A, 2006: Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol, 33, S13-S17.
7. Cain J, Lasley B, Cain G, Feldman E, Stabenfeldt G, 1989: Induction of ovulation in bitches with pulsatile or continuous infusion of GnRH. J Reprod Fertil, 39, 143-147.
8. Cheung L, Wong A, 2008: Gonadotrophin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J., 275, 5479-5495.
9. Coit V, Dowell F, Evans N, 2009: Neutering affects mRNA expression levels for the LH- and GnRH-receptors in the canine urinary bladder. Theriogenology, 71, 239-247.
10. Concannon P, 1989: Induction of fertile oestrus in anoestrus dogs by constant infusion of GnRH agonist. J Reprod Fertil Suppl, 39, 149-160.
11. Concannon P, Temple M, Montanez A, Newton L, 2006: Effects of dose and duration of continuous GnRH agonist treatment on induction of estrus in beagle dogs: competing and concurrent up-regulation and down-regulation of LH release. Theriogenology, 66, 1488-1496.
12. Corrada Y, Hermo G, Johnson C, Trigg T, Gobello C, 2006: Short-term progestin treatment prevent estrous induction by a GnRH agonist implant in anestrous bitches. Theriogenology, 65, 366-373.
13. Dubé J, Frenette G, Tremblay R, Tremblay Y, Bélanger A, 1984: Involution of spontaneous benign prostatic hyperplasia in the dogs under influence of a chronic treatment with a LHRH agonist. Prostate, 5, 417-423.
14. Dubé D, Assaf A, Pelletier G, Labrie F, 1987: Morphological study of the effects of an GnRH agonist on the canine testis after 4months of treatment and recovery. Acta Endocrinol (Copenh.), 116, 413-417.
15. Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M, 2008: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol, 27, 92-99.
16. Fontaine E, Fontbonne A, 2010: Use of deslorelin to control fertility in the bitch. in Symposium deslorelin: deslorelin in practice, 7th EVSSAR Congress. Louvain la Neuve, Belgium, 14th-15th May, pp. 15-17.
17. Fontbonne A, Levy X, Fontaine E, Routier J, 2007: L'insémination artificielle chez les félidés. Bull Acad Vet Fr, 160, 143-151.
18. de Gier J, Winke C, 2010: Use of deslorelin to control hypersexuality in male dogs. in Symposium deslorelin: deslorelin in practice, 7th EVSSAR Congress. Louvain la Neuve, Belgium, May 14th-15th, pp. 9-10.
19. Goericke-Pesch S, Spang A, Schulz M, Ozalp G, Bergmann M, Ludwig C, Hoffmann B, 2009: Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant. Reprod Dom Anim, 44, 302-308.
20. Goericke-Pesch S, Georgiev P, Wehrend A, 2010a: The use of Suprelorin in tomcats abd queens. in Symposium deslorelin: deslorelin in practice, 7th EVSSAR Congress. Louvain la Neuve, Belgium, 14th-15th May, pp. 12-14.
21. Goericke-Pesch S, Wilhelm E, Ludwig C, Desmoulins P, Driancourt M, Hoffmann B, 2010b: Evaluation of the clinical efficacy of Gonazon implants in the treatment of reproductive pathologies, behavioral problems and suppression of reproductive function in the male dog. Theriogenology, 73, 920-926.
22. Ho J, Nagle G, Mathias J, Clench M, Fan X, Kalmaz G, Sallustio J, Eaker E, 1996: Presence of gonadotrophin-releasing hormone (GnRH) receptor mRNA in rat myenteric plexus cell. Comp Biochem Physiol B Biochem Mol Biol, 113, 817-821.
23. Hoffmann B, 2005: New drugs to control canine and feline reproduction. FECAVA-Voorjaarsdagen: International Congress, 15-17 April 2005: EVSSAR Precongress Day, April 14, p11-14. NTH, Amsterdam. pp. 11-14.
24. Inaba T, Umehara J, Mori J, Torii R, Tamada H, Sawada T, 1996: Reversible suppression of pituitary testicular function by a sustained release formulation of a GnRH agonist (leuprolide acetate) in dogs. Theriogenology, 46, 671-677.
25. Inaba T, Tani H, Gonda M, Nakagawa A, Ohmura M, Mori J, Torii R, Tamada H, Sawada T, 1998: Induction of fertile estrus in bitches using a sustained-release formulation of a GnRH agonist (leuprolide acetate). Theriogenology, 49, 975-982.
26. Junaidi A, Williamson P, Martin G, Stanton P, Blackberry M, Cummins J, Trigg T, 2007: Pituitary and testicular endocrine responses to exogenous gonadotrophin-releasing hormone (GnRH) and luteinising hormone in male dogs treated with GnRH agonist implants. Reprod Fertil Dev, 19, 891-898.
27. Kuo Y, Goodwin J, Shahinian V, 2008: Gonadotrophin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. BMC Health Serv Res, 14, 146.
28. Kutzler M, 2005: Induction and synchronization of oestrus in dogs. Theriogenology, 64, 766-775.
29. Kutzler M, Wheeler R, Lamb S, Volkmann D, 2002: Deslorelin implant administration beneath the vulvar mucosa for the induction of synchronous estrus in bitches. 3rd EVSSAR European Congress. Liege, Belgium, p 96.
30. Kutzler M, Stang B, Waldvogel R, Holthofer P, 2006: Administration of a single or multiple doses of injectable long acting deslorelin (GnRH analogue) does not induce oestrus in bitches. 5th Biannual EVSSAR Congress. Budapest, Hungary, 7th-9th April, p 280.
31. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B, 2006: Gonadotropin-releasing hormone agonist in the treatment of prostate cancer. Endocr Rev, 26, 361-379.
32. Lacoste D, St-Arnaud R, Bélanger A, Labrie F, 1988a: A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Mol Cell Endocrinol, 56, 141-147.
33. Lacoste D, St-Arnaud R, Caron S, Bélanger A, Labrie F, 1988b: The rise in testicular androgens during the first days if treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole. J Steroid Biochem, 31, 963-970.
34. Lacoste D, Labrie F, Dubé D, Bélanger A, Tice T, Gilley R, Pledger K, 1989: Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LH-RH agonist [D-Trp6, des-Gly-NH10(2)]LH-RH ethylamide in the dog. J Steroid Biochem, 33, 1007-1011.
35. Limonta P, Montagnani Marelli M, Moretti R, 2001: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drug Saf, 10, 709-720.
36. Lombardini P, Florio S, Pagnini G, Crispino L, Avallone L, 1999: Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer. J Vet Pharmacol Ther, 22, 56-61.
37. Ludwig C, Desmoulins P, Driancourt M, Goericke-Pesch S, Hoffmann B, 2009: Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH agonist azagly-nafarelin as a removable implant "Gonazon": a preclinical trial. Theriogenology, 71, 1037-1045.
38. Mayerhofer A, Dubé D, 1989: Chronic administration of a gonadotropin-releasing hormone (GnRH) agonist affects testicular microvasculature. Acta Endocrinol (Copenh.), 120, 75-80.
39. McRae G, Roberts B, Worden A, Bajka A, Vickery B, 1985: Long term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist. J Reprod Fertil, 74, 389-397.
40. Munson L, Bauman J, Asa C, Jochle W, Trigg T, 2001: Efficacy of the GnRH analogue deslorelin for suppression of oestrous cycles in cats. J Reprod Fertil, 57(Suppl), 269-273.
41. Padula A, 2005: GnRH analogues- agonists and antagonists. Anim Reprod Sci, 88, 115-126.
42. Pagnini U, Florio S, Crispino L, Pagnini G, Colangelo D, Rocco D, Pacilio C, Pacilio M, Macaluso M, Giordano A, 2002: Direct effect of a gonadotropin-releasing hormone agonist on the growth of canine mammary tumour cells. J Cell Biochem, 85, 470-481.
43. Palm J, Reichler I, 2010: Effectiveness of deslorelin acetate for the suppression of heat in the bitch. 7th EVSSAR Congress Louvain La Neuve, Belgium, 14th-15th May, p 87.
44. Ponglowhapan S, Lohachit C, Swangchan-uthai T, Trigg T, 2002: The effect of the GnRH agonist deslorelin on prostatic volume in dogs. 3rd EVSSAR European Congress. Liege, Belgium, May 2002, p 150.
45. Ponglowhapan S, Church D, Scaramuzzi R, Khalid M, 2007: Luteinizing hormone and follicle stimulating hormone receptors and their transcribed genes (mRNA) are present in the lower urinary tract of intact male and female dogs. Theriogenology, 67, 353-366.
46. Ponglowhapan S, Church D, Khalid M, 2008: Differences in the proportion of collagen and muscle in the canine lower urinary tract with regard to gonadal status and gender. Theriogenology, 70, 1516-1524.
47. Prohaczik A, Rubion S, Miller L, Fagerstone K, Driancourt M, 2008: Novel non steroidal long term contraceptive approaches for queens. 6th International Symposium on Canine and Feline Reproduction. Vienna, Austria, 9th-11th July, p 184-186.
48. Reichler I, Hubler M, Jochle W, Trigg T, Piché C, Arnold S, 2003: The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs. Theriogenology, 60, 1207-1216.
49. Reichler I, Hung E, Jochle W, Piché C, Roos M, Hubler M, Arnold S, 2005: FSH and LH plasma levels in bitches with differences in risk for urinary incontinence. Theriogenology, 63, 2164-2180.
50. Reichler I, Barth A, Piché C, Jochle W, Roos M, Hubler M, Arnold S, 2006a: Urodynamic parameters and plasma LH in spayed beagle bitches before and 8weeks after GnRH depot analogue treatment. Theriogenology, 66, 2127-2136.
51. Reichler I, Jochle W, Piché C, Roos M, Arnold S, 2006b: Effect of a long acting GnRH analogue or placebo on plasma LH/FSH, urethral pressure profiles and clinical signs of urinary incontinence due to sphincter mechanism incompetence in bitches. Theriogenology, 66, 1227-1236.
52. Reichler I, Welle M, Eckrich C, Sattler U, Barth A, Hubler M, Nett-Mettler C, Jochle W, Arnold S, 2008: Spaying-induced coat changes: the rôle of gonadotropins, GnRH and GnRH treatment on the hair cycle of female dogs. Vet Dermatol, 19, 77-87.
53. Romagnoli S, 2006: Deslorelin in small animal andrology. 5th Biannual congress, European Veterinary Society for Small Animal Reproduction (EVSSAR). Budapest, Hungary, 7-9 April, pp. 204-207.
54. Romagnoli S, 2007: Diagnostic work-up and medical therapy of canine prostatic diseases. ESAVS Reproduction II, Zurich, Switzerland, 10-14th September 2007.
55. Romagnoli S, Nassuato C, Stelletta C, Mollo A, Gelli D, Lorenzon A, 2005: Serum testosterone concentrations and scrotal diameter in male dogs treated with deslorelin implants. FECAVA-Voorjaarsdagen: International Congress, Amsterdaln 15-17 April 2005: EVSSAR Precongress Day, April 14. NTH, Amsterdam, pp. 27-28.
56. Romagnoli S, Stelletta C, Milani C, Gelli D, Falomo M, Mollo A, 2009: Clinical use of deslorelin for the control of reproduction in the bitch. Reprod Dom Anim, 44, 36-39.
57. Rubion S, Desmoulins P, Rivière-Godet E, Kinziger M, Salavert F, Rutten F, Flochay-Sigognault A, Driancourt M, 2006: Treatment with a subcutaneous GnRH agonist containing controlled release device reversibly prevents puberty in bitches. Theriogenology, 66, 1651-1654.
58. Shahani S, Braga-Basaria M, Basaria S, 2008: Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab, 93, 2042-2049.
59. Smith M, 2004: Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol, 172, S52-S56. discussion S56-57.
60. Smith M, 2006: Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res, 12, 6315s-6319s.
61. Sung M, Armour A, Wright P, 2006: The influence of exogenous progestin on the occurence of proestrous or estrous signs, plasma concentrations of luteinizing hormone and estradiol in deslorelin (GnRH agonist) treated anestrous bitches. Theriogenology, 66, 1513-1517.
62. Tay C, 2002: Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum Fertil (Camb). 5, G35-G37; discussion G38-39, G41-48.
63. Toydemir T, Kiliçarslan M, Olgaç V, 2008: The effect of GnRH analogue deslorelin implants on reproduction in female domestic cats. 6th International Symposium on Canine and Feline Reproduction. Vienna, Austria, 9th-11th July, pp. 262-263.
64. Tremblay Y, Belanger A, 1984: Reversible inhibition of gonadal functions by a potent gonadotrophin-releasing hormone agonist in adult dog. Contraception, 30, 483-497.
65. Tremblay Y, Belanger A, Labrie F, Frenette G, Dubé J, Tremblay R, 1984: Characteristics of the inhibitory effect of chronic treatment with an LHRH agonist on testicular steroidogenesis in the dog. Prostate, 5, 631-638.
66. Trigg T, Yeates K, 2008: The development and use of deslorelin implants to suppress fertility- a synopsis and further advances. 6th International Symposium on Canine and Feline Reproduction. Vienna, Austria, 9th-11th July, pp. 265-266.
67. Trigg T, Wright P, Armour A, Williamson P, Junaidi A, Martin G, Doyle A, Walsh J, 2001: Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domestic dogs. J Reprod Fertil, 57(Suppl.), 255-261.
68. Trigg T, Doyle A, Walsh J, Swangchan-uthai T, 2006: A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology, 66, 1507-1512.
69. Valiente C, Diaz J, Rosa D, Mattioli G, Garcia Romero G, Gobello C, 2009: Effect of a GnRH antagonist on GnRH agonist-implanted anoestrous bitches. Theriogenology, 72, 926-929.
70. Vickery B, McRae G, Bonasch H, 1982: Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs. Prostate, 3, 123-130.
71. Vickery B, McRae G, Briones W, Worden A, Seidenberg R, Schanbacher B, Falvo R, 1984: Effects of an LHRH agonist analog upon sexual function in male dogs. Suppression, reversibility and effect of testosterone replacement. J Androl, 5, 28-42.
72. Vickery B, McRae G, Briones W, Roberts B, Worden A, Schanbacher B, Falvo R, 1985: Doses-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist. J Androl, 6, 53-60.
73. Volkmann D, Kutzler M, Wheeler R, Krekeler N, 2006a: The use of deslorelin implants for the synchronization of estrous bitches. Theriogenology, 66, 1497-1501.
74. Volkmann D, Kutzler M, Wheeler R, Krekeler N, Klewitz J, Lamb S, 2006b: Failure of hCG to support luteal function in bitches after estrus induction using deslorelin implants. Theriogenology, 66, 1502-1506.
75. Warnock J, Bundren J, Morris D, 1998: Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety, 7, 171-177.
76. Welle M, Reichler I, Barth A, Forster U, Sattler U, Arnold S, 2006: Immunohistochemical localization and quantitative assessment of GnRH-, FSH- and LH- receptor mRNA expression in canine skin: a powerful tool to study the pathogenesis of side effects after spaying. Histochem Cell Biol, 126, 527-535.
77. Williams M, Hernandez J, Thompson I, 2005: Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol, 173, 1067-1071.
78. Wright P, Verstegen J, Onclin K, Jochle W, Armour A, Martin G, Trigg T, 2001: Suppression of the oestrous responses of bitches to the GnRH analogue deslorelin by progestin. J Reprod Fertil, Suppl 57, 263-268.
79. Yanovski J, Rose S, Municchi G, Pescovitz O, Hill S, Cassoria F, Cutler GJ, 2003: Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Eng J Med, 348, 942-945.